摘要
目的:比较达格列净与阿格列汀治疗2型糖尿病患者的效果。方法:回顾性分析2018年11月至2022年12月该院收治的100例2型糖尿病患者的临床资料,根据治疗方案不同将其分为对照组47例和观察组53例。对照组予以阿格列汀治疗,观察组予以达格列净治疗,比较两组治疗前后糖代谢指标[空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)]水平、胰岛功能指标[空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)]水平、炎性指标[白细胞介素-6(IL-6)、胱抑素C(CysC)、C反应蛋白(CRP)]水平和不良反应发生率。结果:治疗后,两组FPG、HbA1c、2hPG、HOMA-IR水平均低于治疗前,HOMA-β、FINS水平均高于治疗前,但组间比较,差异均无统计学意义(P>0.05);治疗后,两组IL-6、CysC、CRP水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:达格列净与阿格列汀治疗2型糖尿病患者均能降低糖代谢指标水平,改善胰岛功能指标水平,但达格列净降低炎性指标水平的效果优于阿格列汀治疗。
Objective:To compare effects of Dapagliflozin and Alogliptin in treatment of patients with type 2 diabetes.Methods:The clinical data of 100 patients with type 2 diabetes admitted to the hospital from November 2018 to December 2022 were retrospectively analyzed.According to different treatment options,they were divided into control group(47 cases)and observation group(53 cases).The control group was treated with Alogliptin,while the observation group was treated with Dapagliflozin.The levels of glucose metabolism indicators[fasting blood glucose(FPG),2h postprandial blood glucose(2hPG),glycosylated hemoglobin(HbA1c)],islet function indicators[fasting insulin(FINS),insulin resistance indicator(HOMA-IR),isletβcell secretory function indicator(HOMA-β)]and inflammatory indicators[interleukin-6(IL-6),cystatin C(CysC),C-reactive protein(CRP)]before and after the treatment,and the incidence of adverse reactions during treatment were compared between the two groups.Results:After the treatment,the levels of FPG,HbA1c,2hPG and HOMA-IR in the two groups were lower than those before the treatment,and the levels of HOMA-βand FINS were higher than those before the treatment,but there were no significant differences between the two groups(P>0.05).After the treatment,the levels of IL-6,CysC and CRP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Dapagliflozin and Alogliptin can reduce the levels of glucose metabolism indicators and improve the levels of islet function indicators in the patients with type 2 diabetes,but Dapagliflozin can reduce the levels of inflammatory indicators.It is superior to Alogliptin.
作者
魏美玲
张海涛
范萍
WEI Meiling;ZHANG Haitao;FAN Ping(Department of Endocrine and metabolic diseasas of Guangshan County People‘s Hospital,Xinyang 465450 Henan,China)
出处
《中国民康医学》
2024年第9期149-151,155,共4页
Medical Journal of Chinese People’s Health
关键词
2型糖尿病
阿格列汀
达格列净
糖代谢
胰岛功能
炎性指标
不良反应
Type 2 diabetes
Alogliptin
Dapagliflozin
Glucose metabolism
Islet function
Inflammatory indicator
Adverse reaction
